Zobrazeno 1 - 10
of 534
pro vyhledávání: '"A. I. Parfenov"'
Autor:
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, I. A. Li, D. V. Podolskaya, T. V. Shkurko, B. A. Nanaeva, T. L. Aleksandrov, T. A. Baranova, I. A. Tishaeva, M. Yu. Zvyaglova, A. I. Parfenov
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 20-29 (2021)
Introduction. Tofacitinib is the first member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis (UC). The article presents a three-year Russian experience of tofacitinib use for the treatment of mode
Externí odkaz:
https://doaj.org/article/f0ccd53b02d34cefa5b317533f978e88
Autor:
A. I. Parfenov, O. V. Akhmadullina, N. I. Belostotsky, E. A. Sabelnikova, A. A. Novikov, S. V. Bykova, S. R. Dbar
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 129-137 (2021)
The article describes enteropathy with impaired membrane digestion (EIMD) as a new nosological form. The main clinical manifestation of EIMD is the poor tolerance of food products, in particular carbohydrates and a decrease in the activity of membran
Externí odkaz:
https://doaj.org/article/1b44825614a841e2a95e38c4dd9b4e67
Autor:
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 150-157 (2021)
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We incl
Externí odkaz:
https://doaj.org/article/7b2a05de304e4187a8a9f0dd6dd2c75c
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 228-235 (2021)
Inflammatory bowel disease IBD (Crohns disease CD, ulcerative colitis UC) immune-mediated diseases of the digestive tract of unknown etiology. The basis of the pathogenesis of IBD is a violation of the protective mechanisms of the intestinal barrier
Externí odkaz:
https://doaj.org/article/7158cd69ea6a465790c2f5db9d36a84e
Autor:
A. I. Parfenov
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 243-248 (2021)
The article describes the main achievements in the knowledge of celiac disease a mysterious disease known since the time of Hippocrates. The most important discovery was made by Willem-Karel Dicke, in 1941 linking the cause of the disease with the co
Externí odkaz:
https://doaj.org/article/d3d89353b42940deb3893f67f56991e5
Autor:
S. V. Bykova, Elena A. Sabelnikova, R. B. Gudkova, K. K. Noskova, L. M. Krums, A. I. Parfenov
Publikováno v:
Терапевтический архив, Vol 93, Iss 2, Pp 145-149 (2021)
Aim. To determine the frequency of celiac disease (CD) among gastroenterological patients and criteria for its active detection. Materials and methods. 1.358 patients referred for gastroenterologist consultation from 2016 to 2019 was conducted, of
Externí odkaz:
https://doaj.org/article/ee72c6547b3647298dedd962a7e35c3f
Publikováno v:
Терапевтический архив, Vol 92, Iss 12, Pp 4-9 (2020)
Chronic intestinal pseudo-obstruction a rare violation of the motor skills of the gastrointestinal complex, similar to mechanical obstruction, but without a mechanical obstacle. The development of chronic intestinal pseudo-obstruction is caused by a
Externí odkaz:
https://doaj.org/article/dea80d3eedf34a789c774c81f92fd2cf
Publikováno v:
Терапевтический архив, Vol 92, Iss 12, Pp 36-42 (2020)
The current concepts of the short bowel syndrome and malabsorption after intestinal surgery are generally accepted, but do not fully reflect the patients condition, making it difficult to diagnose and treat it. Aim.The purpose of the study is to a
Externí odkaz:
https://doaj.org/article/b8d70f6f80604f67b6807c9904112d43
Publikováno v:
Терапевтический архив, Vol 92, Iss 2, Pp 104-111 (2020)
Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxy
Externí odkaz:
https://doaj.org/article/7d742ee1631244bba86b71c6445099c9
Publikováno v:
Терапевтический архив, Vol 92, Iss 2, Pp 81-84 (2020)
The patient E., aged 39, was described with a severe form of the irritable bowel syndrome that developed after the stress. In addition to the clinical manifestations of IBS, the patient got the somatoform disorders, which manifested itself with a lar
Externí odkaz:
https://doaj.org/article/59cea840fab14fac888a06bc8ea15ff9